A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an open label, multicenter study with two phases:

* A dose escalation phase of Romidepsin administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)administered every 3 weeks for 8 cycles in patients with T-cell lymphoma.
* An expansion phase in order to assess the safety and the efficacy of the association of the recommended dose of Romidepsin associated with CHOP in a population of patients with T-cell lymphoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma

NCT01590732

Mycosis Fungoides Recurrent Anaplastic Large Cell Lymphoma Recurrent Angioimmunoblastic T-Cell Lymphoma +8 more

COMPLETED PHASE1

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

NCT02181218

Lymphoma, T-Cell, Cutaneous Lymphoma, T-Cell, Peripheral Hodgkin Disease +1 more

COMPLETED PHASE1

Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

NCT04233697

Lymphoma, T-Cell

WITHDRAWN PHASE1

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516

Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma +14 more

ACTIVE_NOT_RECRUITING PHASE2

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

NCT01998035

Lymphoid Malignancies Lymphoma Hodgkin Lymphoma +1 more

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the study is to determine the feasibility of the combination and the recommended dose (RD) of Romidepsin when administered in association with CHOP in a population of patients with newly diagnosed Peripheral T-cell lymphoma (PTCL) as measured by the toxicities during treatment.

Secondary objectives:

* To assess the safety of the association Romidepsin and CHOP,
* To assess the efficacy of the association of Romidepsin and CHOP: response rate and complete response rate, progression-free survival, response duration and overall survival.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral T Cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma

Intervention Type DRUG

Romidepsin and CHOP

Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma

Intervention Type DRUG

Romidepsin and CHOP

Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma

Intervention Type DRUG

Romidepsin and CHOP

Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with histologically confirmed Peripheral T-cell Lymphoma (PTCL), not previously treated ; all subtypes may be included except HTLV-1-related T-cell lymphoma, cutaneous T-cell lymphoma (mycosis fungoid and Sézary syndrome), and ALK+ PTCL,
2. Ann Arbor stages II - IV
3. Aged from 18 to 80 years,
4. ECOG performance status 0, 1 or 2,
5. Signed informed consent,
6. Negative pregnancy test for females of childbearing potential (FCBP),
7. FCBP using an effective method of birth control (i.e. hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide or abstinence) for the treatment period and for 1 month thereafter; Males using an effective method of birth control for the treatment period and 3 months thereafter,
8. Life expectancy of ≥ 90 days (3 months)

Exclusion Criteria

1. Other types of lymphomas, e.g. B-cell lymphoma
2. Ann Arbor stage I
3. Previous treatment for PTCL with immunotherapy or chemotherapy except for short-term corticosteroids before inclusion
4. Previous radiotherapy for PTCL except if localized to one lymph node area
5. Central nervous system - meningeal involvement
6. Contraindication to any drug contained in the chemotherapy regimen
7. HIV infection, active hepatitis B or C
8. Any serious active disease or co-morbid medical condition (according to investigator's decision)
9. Any of the following laboratory abnormalities

* Absolute neutrophil count (ANC) \< 1,500 cells/mm3 (1.5 x 109/L),
* Platelet count \< 100,000/mm3 (100 x 109/L), or 75,000 if bone marrow is involved,
* Serum SGOT/AST or SGPT/ALT ≥ 5.0 x upper limit of normal (ULN),
* Serum total bilirubin \> 2.0 mg/dL (34 µmol/L), except in case of hemolytic anemia,
* Low K+ (inferior to low normal level) and low Mg+ (inferior to low normal level)levels, except if corrected before beginning the chemotherapy,
10. Use of oral contraceptive and contraceptive patches,
11. Calculated creatinine clearance (Cockcroft-Gault formula) of \< 50 mL /min,
12. Prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for ≥ 3 years,
13. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form,
14. Left Ventricular Ejection Fraction \< 45% (calculated by echocardiographic or scintigraphic methods),
15. Patients with congenital long QT syndrome, history of significant cardiovascular disease and/or taking drugs leading to significant QT prolongation,
16. Corrected QT interval \> 480 msec (using the fridericia formula)
17. Use of any standard or experimental anti-cancer drug therapy within 28 days of the initiation (Day 1) of study drug ,
18. Pregnant or lactating females or women of childbearing potential not will-ing to use an adequate method of birth control for the duration of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No